Renowned economist Richard Werner challenges traditional views on banks, stating they have the unique power to create money.

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for ...

After a rough reception and a rebrand to support users of GLP-1 drugs, Peoplehood is selling its assets to WeightWatchers.

This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...

In what Epic Games’ CEO describes as a “[t]otal victory in the Epic v. Google appeal”, on July 31, the United States Court of Appeals for the ...

Coal's popularity as an investment has been going down the chute since the early 2000s, but energy consulting firm group Wood Mackenzie recently laid out a trajectory that coal demand could stay ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

The FTSE 100 slid about 0.3 per cent early doors due chiefly to a raft of blue chips moving ex-dividend. Hikma, which reported today, led the actual fallers, slipping about 8 per cent after profits ...

GLP-1 drugs have shifted from medical to mainstream, and the impact is rippling far beyond health. From luxury to lifestyle, ...